Biolegend, 135210, APC anti-mouse CD279 (PD-1) Antibody, 100μg

CD279, also known as programmed death-1 (PD-1), is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is expressed on activated splenic T and B cells and thymocytes. It is induced on activated myeloid cells as well. PD-1 is involved in lymphocyte clonal selection and peripheral tolerance through binding its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2). It has been reported that PD-1 and PD-L1 interactions are critical to positive selection and play a role in shaping the T cell repertoire. PD-L1 negative costimulation is essential for prolonged survival of intratesticular islet allografts.
100μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: PD-1 cDNA followed by PD-1-Ig fusion protein
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration: 0.2 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser: Red Laser (633 nm)
Application Notes: Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue3, in vivo blocking of PD-1 binding to its ligands2,3, and spatial biology (IBEX)5,6.
Application References(PubMed link indicates BioLegend citation): Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block) Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block) Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed Xiao X, et al. 2023. Nat Commun. 14:2859. PubMed Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed Campisi L, et al. 2022. Nature. 606:945. PubMed Chen Q, et al. 2022. Cell Rep. 39:110990. PubMed Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed Molina MS, et al. 2022. PLoS One. 17:e0273075. PubMed Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed Horkova V, et al. 2023. Nat Immunol. 24:174. PubMed Xiao J, et al. 2023. J Clin Invest. 133: . PubMed Ivasko SM, et al. 2023. Front Immunol. 13:1023206. PubMed Friedman D, et al. 2022. J Immunol. 208:1845. PubMed Xie A et al. 2017. Endocrinology. 158(10):3140-3151 . PubMed Zhou J, et al. 2019. Immunity. 50:403. PubMed Qi Z, et al. 2022. Nat Commun. 13:182. PubMed Wu Q, et al. 2021. Cancer Commun (Lond). Online ahead of prin. PubMed Lino AC et al. 2018. Immunity. 49(1):120-133 . PubMed Wang J, et al. 2019. Front Immunol. 9:3157. PubMed Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed Smith T, et al. 2014. J Immunol. 193:3409. PubMed Waide ML, et al. 2020. Cell Rep. 33:108503. PubMed Almshayakhchi R, et al. 2021. Front Oncol. 11:636977. PubMed Stokes J, et al. 2020. Oncoimmunology. 9:1758011. PubMed Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed Stewart JM, et al. 2020. ACS Biomater Sci Eng. 6:5941. PubMed Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed Lasso P, et al. 2020. Front Immunol. 584959:11. PubMed Imani J, et al. 2021. JCI Insight. 6:. PubMed Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed Pilones KA, et al. 2020. Cancer Immunol Res. 8:1054. PubMed LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed Shen M, et al. 2022. Nat Cancer. 3:60. PubMed Webb ER, et al. 2022. iScience. 25:104995. PubMed Koikawa K, et al. 2021. Cell. 184:4753. PubMed Moon S, et al. 2021. J Exp Med. 218:. PubMed Shiozawa S, et al. 2022. iScience. 25:103537. PubMed Mandal RK, et al. 2021. Cell Reports. 35(6):109094. PubMed Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed Onishi M, et al. 2015. J Immunol. 194:2673. PubMed Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed Montalban-Arques A, et al. 2021. Cell Host Microbe. :. PubMed Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed Zheng Y, et al. 2022. J Immunol. 208:501. PubMed Molina MS, et al. 2021. Front Immunol. 12:699128. PubMed Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed Shimba A et al. 2018. Immunity. 48(2):286-298 . PubMed Wagner AK, et al. 2022. iScience. 25:105137. PubMed Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed Charlton J, et al. 2015. PLoS One. 10:119200. PubMed Li M, et al. 2020. J Immunother Cancer. 8:00. PubMed Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed
RRID: AB_2251944 (BioLegend Cat. No. 135209) AB_2159183 (BioLegend Cat. No. 135210)
Structure: A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.
Distribution: Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.
Function: Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.
Ligand/Receptor: B7-H1 (PD-L1) and B7-DC (PD-L2)
Cell Type: B cells, T cells
Biology Area: Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family: CD Molecules, Immune Checkpoint Receptors
Antigen References: 1. Nishimura H, et al. 2001. Science 291:319 2. Agata Y, et al. 1996. Int. Immunol. 8:765 3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706 4. Barber DL, et al. 2006. Nature 439:682 5. Keir ME, et al. 2005. J. Immunol. 175:7372 6. Koehn BH. et al. 2008. J Immunol. 181:5313
Gene ID: 18566
UniProt: View information about CD279 on UniProt.org
Clone: 29F.1A12
Regulatory Status: RUO
Other Names: PD-1, Programmed Death-1, PDCD1
Isotype: Rat IgG2a, κ